argenx SE (NASDAQ:ARGX) Shares Bought by Northern Trust Corp

Northern Trust Corp lifted its position in shares of argenx SE (NASDAQ:ARGX - Free Report) by 42.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 54,128 shares of the company's stock after purchasing an additional 16,188 shares during the period. Northern Trust Corp owned about 0.09% of argenx worth $33,289,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of ARGX. GeoWealth Management LLC lifted its position in shares of argenx by 56.3% during the 4th quarter. GeoWealth Management LLC now owns 50 shares of the company's stock worth $31,000 after buying an additional 18 shares during the last quarter. Whipplewood Advisors LLC acquired a new stake in shares of argenx during the fourth quarter worth about $37,000. Global Retirement Partners LLC lifted its holdings in shares of argenx by 369.2% in the 4th quarter. Global Retirement Partners LLC now owns 61 shares of the company's stock valued at $38,000 after purchasing an additional 48 shares during the last quarter. FIL Ltd acquired a new stake in shares of argenx in the 4th quarter valued at about $38,000. Finally, Jones Financial Companies Lllp grew its stake in argenx by 1,016.7% during the 4th quarter. Jones Financial Companies Lllp now owns 67 shares of the company's stock worth $41,000 after buying an additional 61 shares during the last quarter. 60.32% of the stock is owned by hedge funds and other institutional investors.

argenx Price Performance

Shares of NASDAQ ARGX traded down $10.20 on Wednesday, hitting $532.27. The company's stock had a trading volume of 486,197 shares, compared to its average volume of 322,097. The stock has a 50 day moving average of $593.35 and a 200-day moving average of $613.35. The company has a market capitalization of $32.50 billion, a price-to-earnings ratio of -604.85 and a beta of 0.57. argenx SE has a 12-month low of $352.77 and a 12-month high of $678.21.

argenx (NASDAQ:ARGX - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported $2.58 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.32 by $0.26. The company had revenue of $1.35 billion for the quarter, compared to analyst estimates of $748.34 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. Sell-side analysts expect that argenx SE will post 3.13 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on ARGX shares. HC Wainwright reissued a "buy" rating and issued a $720.00 price objective on shares of argenx in a report on Tuesday, April 8th. JMP Securities set a $699.00 price objective on shares of argenx in a research report on Wednesday. Robert W. Baird upgraded shares of argenx from a "neutral" rating to an "outperform" rating and set a $680.00 target price for the company in a research note on Tuesday. Oppenheimer upped their price objective on argenx from $704.00 to $708.00 and gave the company an "outperform" rating in a research note on Friday, May 9th. Finally, Wells Fargo & Company lifted their target price on argenx from $723.00 to $741.00 and gave the company an "overweight" rating in a research note on Friday, February 28th. Two analysts have rated the stock with a hold rating, twenty have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $698.11.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.